TRANSVAC: new vaccines faster

Welcome to TRANSVAC, a collaborative infrastructure project funded under the European Commission’s (EC) 7th Framework Programme (FP7). The project is the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC was designed in order to enhance European research and training and foster the seamless implementation of a permanent research infrastructure for early vaccine development in Europe.

In order to reach its ambitious goal, TRANSVAC carries out activities at various levels. On this website you can find out about how to benefit from TRANSVAC’s portfolio of activities, learn how to apply for access to the TRANSVAC’s high-quality Infrastructure Free Services and Paid Services, how to participate in the free Workshops on Animal Models or in the free Modular Course on Concepts on Vaccine Development. Finally, TRANSVAC looks to the future and is exploring the implementation of a road map towards a sustainable European vaccine development platform beyond TRANSVAC. This is done by the European Vaccine Development Stakeholder Working Groups.

News

10 March 2015

FLUCOP launched 1 March 2015

To improve the toolbox available to evaluate seasonal flu vaccines, European public and private research institutions are joining together in FLUCOP, a €13.9M project funded by the Innovative Medicines Initiative (IMI). Full Press Release

05 March 2015

IPROVE Vaccine Research Innovation Workshop

This high-level stakeholder consultation workshop  (12 - 13 March in Brussels) organised by the IPROVE FP7 project consortium will feature participation from... 

11 February 2015

Exciting career opportunity as Vaccine Management Assistant at EVI - new deadline

Deadline for applications 27 February 2015 17:00 CET.  Download PDF-version

EVI has an exciting career opportunity for junior and motivated individual to join the organisation in an eighteen month full time position as Vaccine Management Assistant (VMA) for a phase I vaccine clinical trial.